-
MDA 2026: Dyne advances DMD therapy z-rostudirsen toward approval
Dyne Therapeutics is advancing its investigational exon-skipping therapy zeleciment rostudirsen (z-rostudirsen), formerly known as DYNE-251,
-
MDA 2026: This year’s MDA meeting provided a glimpse into the future
Muscular Dystrophy News Today is wrapping up coverage of the 2026 Muscular Dystrophy Association (MDA)
-
How to Make Vocational Training Affordable
There are many reasons a person with a disability might choose vocational training. One prominent
-
I’m thankful for a big family that gives my DMD sons a full social life
The comment comes in many forms: “I don’t know how you do it.” “You have
-
17-year-old advocate shares her NMOSD story to raise awareness
In 2018, when Nell Choi was 9 years old, she began experiencing symptoms that led
-
MDA 2026: ‘Body of evidence for Elevidys continues to grow’
Boys with Duchenne muscular dystrophy (DMD) who received Sarepta Therapeutics’ gene therapy Elevidys (delandistrogene moxeparvovec-rokl)
-
Sarepta Announces Plans to Submit sNDAs for AMONDYS 45 and VYONDYS 53
Today, Sarepta Therapeutics announced plans to submit supplemental New Drug Applications (sNDAs) to the U.S.
-
Sarepta Therapeutics is preparing to submit supplemental new drug applications (sNDAs) to the FDA for converting the accelerated approvals of AMONDYS 45 and VYONDYS 53 to traditional approvals
Sarepta Therapeutics is preparing to submit supplemental new drug applications (sNDAs) to the FDA for
-
The CureDuchenne Clinic Relocates in Greater Dallas to Meet Rising Demand for Specialized Neuromuscular Care
Expanded Facility Delivers Comprehensive, Multidisciplinary Care, Removing Barriers for Patients with Duchenne and Becker Muscular
-
MDA 2026: FDA decision on deramiocel for DMD expected by August
The latest Phase 3 trial results continue showing that deramiocel, an investigational cell therapy for
